Top Markets
Coin of the day
Crossject Société Anonyme Crossject Société Anonyme

Crossject Société Anonyme

ALCJ
Rank in Stocks #12721
Crossject Société Anonyme develops needle-free injection systems. The company... Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Share Price
$2.03
Market Cap
$121.44M
Change (1 day)
-0.93%
Change (1 year)
-1.97%
Country
FR
Trade Crossject Société Anonyme (ALCJ)

Category

P/B ratio for Crossject Société Anonyme (ALCJ)
P/B ratio as of July 2026 TTM: -19.13
According to Crossject Société Anonyme latest financial reports and stock price the company's current price-to-book ratio (TTM) is -19.13. At the end of 2023 the company had a P/B ratio of -34.70.
P/B ratio history for Crossject Société Anonyme from 2010 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) -19.13 -49.09%
2024 -37.58 8.29%
2023 -34.70 -158.98%
2022 58.83 -594.78%
2021 -11.89 -81.50%
2020 -64.28 -524.02%
2019 15.16 54.90%
2018 9.79 46.48%
2017 6.68 29.69%
2016 5.15 -33.97%
2015 7.80 105.46%
2014 3.80 -92.39%
2013 49.91 -339.62%
2012 -20.83 12.72%
2011 -18.48 290.65%
2010 -4.73 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
8.0767 -142.21%
US
1.954 -110.21%
FR
5.8147 -130.39%
DE
8.564 -144.76%
JP
1.7598 -109.20%
US